Ignite Creation Date:
2024-05-05 @ 11:26 PM
Last Modification Date:
2024-10-26 @ 10:33 AM
Study NCT ID:
NCT01322477
Status:
UNKNOWN
Last Update Posted:
2011-03-24
First Post:
2011-02-14
Brief Title:
Contribution of F-18 Fluoro-Deoxy-Glucose PETCT Positron Emission Tomography to the Assessment of HCC Hepato-cellular Carcinoma Treatment Efficiency
Sponsor:
Hadassah Medical Organization
Organization:
Hadassah Medical Organization
Study Overview
Official Title:
None
Status:
UNKNOWN
Status Verified Date:
2011-01
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HCC
Brief Summary:
HCC Hepato-cellular Carcinoma is the fifth most frequent cancer in humans and its prevalence is growing The most effective treatment of HCC is surgical and includes resection and liver transplantation however only 20 of the patients can be treated surgically Local interventional therapy such as radiofrequency RF ablation and transarterial embolization is also used
Recurrence rate is very high and extrahepatic disease develops in about 30 of the cases and in up to 20 after liver transplantation
Systemic treatment is thus an option Sorafenib multi-kinase inhibitor is the first agent to significantly improve the overall survival in advanced HCC However the drug has serious side effects and is very expensive
PETCT with F18-FDG is a common tool for systemic evaluation and staging of various tumors
The value of the FDG PET for evaluation of HCC is controversial in particular due to the unique metabolic pathway of glucose in the HCC cells Since 2007 more and more studies suggest the feasibility of FDG PETCT for monitoring local recurrence especially after RF and metastatic spread of HCC including detection of active disease only suspected by AFP alphafoetoprotein elevation
Early detection of treatment response to therapy by whole body FDG PETCT allows for change of treatment as early as possiblewhen the tumor is non-responsive before serious side effects appear or before depletion of body resources
The aim of our study is to investigate the contribution of FDG PETCT to assessment of treatment response
Recurrence rate is very high and extrahepatic disease develops in about 30 of the cases and in up to 20 after liver transplantation
Systemic treatment is thus an option Sorafenib multi-kinase inhibitor is the first agent to significantly improve the overall survival in advanced HCC However the drug has serious side effects and is very expensive
PETCT with F18-FDG is a common tool for systemic evaluation and staging of various tumors
The value of the FDG PET for evaluation of HCC is controversial in particular due to the unique metabolic pathway of glucose in the HCC cells Since 2007 more and more studies suggest the feasibility of FDG PETCT for monitoring local recurrence especially after RF and metastatic spread of HCC including detection of active disease only suspected by AFP alphafoetoprotein elevation
Early detection of treatment response to therapy by whole body FDG PETCT allows for change of treatment as early as possiblewhen the tumor is non-responsive before serious side effects appear or before depletion of body resources
The aim of our study is to investigate the contribution of FDG PETCT to assessment of treatment response
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None